New drug formulation slows kidney disease progression in clinical trial

A targeted-release version of the steroid budesonide reduced disease markers in patients with immunoglobulin A nephropathy, a leading cause of kidney failure. The NEFIGAN trial results suggest a potential path to slowing progression of this serious kidney condition, opening commercial opportunities in a treatment area with few effective options.

Originaltitel: Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: insights from the NEFIGAN trial